Share “Conn. gets $1.7 M in diabetes drug settlement”

Conn. gets $1.7 M in diabetes drug settlement

Associated Press Published: November 17, 2012

HARTFORD, Conn. (AP) — Connecticut is getting nearly $1.7 million to settle claims that British drug maker GlaxoSmithKline LLC deceptively promoted the diabetes drug Avandia.

The payment is part of a $90 million settlement between GlaxoSmithKline and attorneys general from 38 different states.

Connecticut officials say $100,000 from the state's share of the settlement will support the Department of Consumer Protection. Another $100,000 will go to the Office of the Attorney General's General Consumer Fund.

Attorney generals say GlaxoSmithKline misrepresented Avandia's cardiovascular risks and safety profile. The agreement requires the company to reform its marketing practices and to publicize information about any company-sponsored clinical trials on its diabetes drugs.

GlaxoSmithKline doesn't admit any wrongdoing. A spokeswoman says the company firmly believes it acted responsibly in testing, marketing and monitoring the safety of Avandia.

The settlement was announced on Thursday.